A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 1, 2013, Pages 85-95

  Dobri, Nicoleta ^a   Qin, Qiong ^a   Kong, Jian ^a   Yamamoto, Kazunori ^a   Liu, Zhao ^a   Moiseyev, Gennadiy ^b   Ma, Jian Xing ^b   Allikmets, Rando ^a,c   Sparrow, Janet R ^a,c   Petrukhin, Konstantin ^a  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 (2 [TRIFLUOROMETHYL]PHENYL)PIPERIDINE 1 CARBOXAMIDO)BENZOIC ACID; A 1120; BENZOIC ACID DERIVATIVE; LIPOFUSCIN; PREALBUMIN; RETINOID; RETINOL; RETINOL BINDING PROTEIN 4; UNCLASSIFIED DRUG; A1120 AGENT; ABC TRANSPORTER; ABCA4 PROTEIN, MOUSE; ANTINEOPLASTIC AGENT; FENRETINIDE; HYDROLASE; LIGAND; PIPERIDINE DERIVATIVE; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, HUMAN; RBP4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEACHING; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; ENZYME BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; LIPOFUSCINOSIS; MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RETINA MACULA AGE RELATED DEGENERATION; STARGARDT DISEASE; 129 MOUSE; ANIMAL; C57BL MOUSE; CATTLE; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; PATHOLOGY; RETINA MACULA DEGENERATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CATTLE; DISEASE MODELS, ANIMAL; FENRETINIDE; HUMANS; HYDROLASES; LIGANDS; LIPOFUSCIN; MACULAR DEGENERATION; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PIPERIDINES; PREALBUMIN; RETINOIDS; RETINOL-BINDING PROTEINS, PLASMA;

MLCS; MLOWN;

EID: 84874513343     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10050     Document Type: Article

References (48)

1. Petrukhin K. New therapeutic targets in atrophic age-related macular degeneration. Expert Opin Ther Targets. 2007;11: 625-639.
2. Spaide RF. Fundus autofluorescence and age-related macular degeneration. Ophthalmology. 2003;110:392-399.
3. von Ruckmann A, Fitzke FW, Bird AC. Fundus autofluorescence in age-related macular disease imaged with a laser scanning ophthalmoscope. Invest Ophthalmol Vis Sci. 1997; 38:478-486.
4. Holz FG, Bellman C, Staudt S, Schutt F, Volcker HE. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2001;42:1051-1056.
5. Feeney-Burns L, Hilderbrand ES, Eldridge S. Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells. Invest Ophthalmol Vis Sci. 1984;25:195-200.
6. Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res. 2005;80:595-606.
7. Delori FC. RPE lipofuscin in ageing and age-related macular degeneration. In: G. Coscas FCP, ed. Retinal Pigment Epithelium and Macular Disease (Documenta Ophthalmologica). Dordrecht, The Netherlands: Kluwer Academic Publishers; 1995:37-45.
8. Dorey CK, Wu G, Ebenstein D, Garsd A, Weiter JJ. Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration. Invest Ophthalmol Vis Sci. 1989;30: 1691-1699.
9. Sparrow JR, Fishkin N, Zhou J, et al. A2E, a byproduct of the visual cycle. Vision Res. 2003;43:2983-2990.
10. Sparrow JR, Gregory-Roberts E, Yamamoto K, et al. The bisretinoids of retinal pigment epithelium. Prog Retin Eye Res. 2012;31:121-135.
11. Radu RA, Han Y, Bui TV, et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci. 2005;46:4393-4401.
12. Radu RA, Mata NL, Nusinowitz S, Liu X, Sieving PA, Travis GH. Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci U S A. 2003;100:4742-4747.
13. Maeda A, Maeda T, Golczak M, et al. Effects of potent inhibitors of the retinoid cycle on visual function and photoreceptor protection from light damage in mice. Mol Pharmacol. 2006;70:1220-1229.
14. Palczewski K. Retinoids for treatment of retinal diseases. Trends Pharmacol Sci. 2010;31:284-295.
15. Berni R, Formelli F. In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences. FEBS Lett. 1992;308:43-45.
16. Schaffer EM, Ritter SJ, Smith JE. N-(4-hydroxyphenyl)retinamide (fenretinide) induces retinol-binding protein secretion from liver and accumulation in the kidneys in rats. J Nutr. 1993;123:1497-1503.
17. Adams WR, Smith JE, Green MH. Effects of N-(4-hydroxyphenyl) retinamide on vitamin A metabolism in rats. Proc Soc Exp Biol Med. 1995;208:178-185.
18. Fontana JA, Rishi AK. Classical and novel retinoids: their targets in cancer therapy. Leukemia. 2002;16:463-472.
19. Holmes WF, Soprano DR, Soprano KJ. Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines. J Cell Physiol. 2004;199:317-329.
20. Puduvalli VK, Saito Y, Xu R, Kouraklis GP, Levin VA, Kyritsis AP. Fenretinide activates caspases and induces apoptosis in gliomas. Clin Cancer Res. 1999;5:2230-2235.
21. Simeone AM, Ekmekcioglu S, Broemeling LD, Grimm EA, Tari AM. A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther. 2002;1:1009-1017.
22. Tu Y, Jerry DJ, Pazik B, Smith Schneider S. Sensitivity to DNA damage is a common component of hormone-based strategies for protection of the mammary gland. Mol Cancer Res. 2005;3: 435-442.
23. Samuel W, Kutty RK, Nagineni S, Vijayasarathy C, Chandraratna RAS, Wiggert B. N-(4-hydroxyphenyl)retinamide induces apoptosis in human retinal pigment epithelial cells: retinoic acid receptors regulate apoptosis, reactive oxygen species generation, and the expression of heme oxygenase-1 and Gadd153. J Cell Physiol. 2006;209:854-865.
24. Cohen SM, Storer RD, Criswell KA, et al. Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance. Toxicol Sci. 2009;111:4-18.
25. Decensi A, Zanardi S, Argusti A, Bonanni B, Costa A, Veronesi U. Fenretinide and risk reduction of second breast cancer. Nat Clin Pract Oncol. 2007;4:64-65.
26. Turton JA, Willars GB, Haselden JN, Ward SJ, Steele CE, Hicks RM. Comparative teratogenicity of nine retinoids in the rat. Int J Exp Pathol. 1992;73:551-563.
27. Motani A, Wang Z, Conn M, et al. Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo. J Biol Chem. 2009;284:7673-7680.
28. Moiseyev G, Crouch RK, Goletz P, Oatis J Jr, Redmond TM, Ma JX. Retinyl esters are the substrate for isomerohydrolase. Biochemistry. 2003;42:2229-2238.
29. Maiti P, Kong J, Kim SR, Sparrow JR, Allikmets R, Rando RR. Small molecule RPE65 antagonists limit the visual cycle and prevent lipofuscin formation. Biochemistry. 2006;45:852-860.
30. Kim SR, Fishkin N, Kong J, Nakanishi K, Allikmets R, Sparrow JR. Rpe65 Leu450Met variant is associated with reduced levels of the retinal pigment epithelium lipofuscin fluorophores A2E and iso-A2E. Proc Natl Acad Sci U S A. 2004;101:11668-11672.
31. Gamble MV, Ramakrishnan R, Palafox NA, Briand K, Berglund L, Blaner WS. Retinol binding protein as a surrogate measure for serum retinol: studies in vitamin A-deficient children from the Republic of the Marshall Islands. Am J Clin Nutr. 2001;73: 594-601.
32. Garwin GG, Saari JC. High-performance liquid chromatography analysis of visual cycle retinoids. Methods Enzymol. 2000; 316:313-324.
33. Noy N, Xu ZJ. Interactions of retinol with binding proteins: implications for the mechanism of uptake by cells. Biochemistry. 1990;29:3878-3883.
34. Cogan U, Kopelman M, Mokady S, Shinitzky M. Binding affinities of retinol and related compounds to retinol binding proteins. Eur J Biochem. 1976;65:71-78.
35. Sabichi AL, Xu H, Fischer S, et al. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites. Clin Cancer Res. 2003;9:4606-4613.
36. Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM. Retinoid receptor-dependent and-independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res. 1999;59:14-18
37. Lee JW, Lee YC, Na SY, Jung DJ, Lee SK. Transcriptional coregulators of the nuclear receptor superfamily: coactivators and corepressors. Cell Mol Life Sci. 2001;58:289-297.
38. Savkur RS, Burris TP. The coactivator LXXLL nuclear receptor recognition motif. J Pept Res. 2004;63:207-212.
39. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995; 377:454-457.
40. Mandal MN, Moiseyev GP, Elliott MH, et al. Alpha-phenyl-Ntert-butylnitrone (PBN) prevents light-induced degeneration of the retina by inhibiting RPE65 protein isomerohydrolase activity. J Biol Chem. 2011;286:32491-32501.
41. Boyer NP, Higbee D, Currin MB, et al. Lipofuscin and Nretinylidene-N-retinylethanolamine (A2E) accumulate in retinal pigment epithelium in absence of light exposure: their origin is 11-cis-retinal. J Biol Chem. 2012;287:22276-22286.
42. Golczak M, Kuksa V, Maeda T, Moise AR, Palczewski K. Positively charged retinoids are potent and selective inhibitors of the trans-cis isomerization in the retinoid (visual) cycle. Proc Natl Acad Sci U S A. 2005;102:8162-8167.
43. Kubota R, Boman NL, David R, Mallikaarjun S, Patil S, Birch D. Safety and effect on rod function of ACU-4429, a novel smallmolecule visual cycle modulator. Retina. 2012;32:183-188.
44. Mata NL, Phan K, Han Y. Assay of retinol-binding proteintransthyretin interaction and techniques to identify competing ligands. Methods Mol Biol. 2010;652:209-227.
45. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356-362.
46. Amengual J, Golczak M, Palczewski K, von Lintig J. Lecithin: retinol acyltransferase is critical for cellular uptake of vitamin A from serum retinol-binding protein. J Biol Chem. 2012;287: 24216-24227.
47. Quadro L, Blaner WS, Salchow DJ, et al. Impaired retinal function and vitamin A availability in mice lacking retinolbinding protein. Embo J. 1999;18:4633-4644.
48. Chichili GR, Nohr D, Schaffer M, von Lintig J, Biesalski HK. beta-Carotene conversion into vitamin A in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2005;46: 3562-3569.